Immunome, Inc.
IMNM
$15.67
-$0.82-4.97%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Net Income | 19.12% | 11.60% | -174.29% | -1,290.60% | -904.33% |
| Total Depreciation and Amortization | 92.20% | 204.27% | 188.74% | 141.31% | 100.15% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -74.71% | -71.59% | 90.95% | 4,191.39% | 4,080.49% |
| Change in Net Operating Assets | -230.92% | 37.34% | 23.98% | -91.43% | -125.94% |
| Cash from Operations | -194.66% | -255.80% | -1,363.98% | -2,786.81% | -1,526.49% |
| Capital Expenditure | -994.83% | -1,804.08% | -6,338.99% | -9,373.29% | -844.59% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 118.48% | 116.58% | 18.94% | -- | -- |
| Cash from Investing | 83.06% | 36.78% | -179.04% | -22,431.23% | -28,656.18% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -17.53% | -16.71% | 63,049.88% | 692,967.65% | 691,470.59% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -111.20% | -111.35% | -113.13% | -33.80% | -- |
| Cash from Financing | -45.75% | -45.41% | 106.63% | 353.04% | 989,644.12% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -116.82% | -105.38% | -42.99% | 2.15% | 3,269.15% |